Skip to main content

Table 1 Individual CpG sites in metformin transporter genes that exhibit differential DNA methylation in human liver according to diabetes medication and non-diabetic subjects (n = 93)

From: Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver

Probe ID

Chr

Position

Gene region

Non-diabetics (n = 60)

No medication (n = 3)

Metformin (n = 20)

Insulin + Metformin (n = 10)

P-ANCOVA

q value

SLC22A1

 cg13434757

6

160541976

TSS1500

52.0 ± 0.8

56.0 ± 3.5

48.8 ± 1.3a

56.2 ± 1.9a, b

0.010

0.022

 cg05314142

6

160542711

TSS200

41.7 ± 0.7

43.2 ± 3.3

38.9 ± 1.2

46.3 ± 1.7a, b

0.009

0.022

 cg24864413

6

160542732

TSS200

40.3 ± 0.5

44.5 ± 2.3b

39.5 ± 0.9

47.3 ± 1.2a, b

<0.0001

< 0.0001

 cg22416916

6

160542770

TSS200

36.6 ± 0.5

39.5 ± 2.1

35.2 ± 0.8

40.7 ± 1.1a, b

0.002

0.013

 cg13466809

6

160542944

1stExon;5’UTR

35.5 ± 0.4

36.5 ± 2.0

34.3 ± 0.7

39.0 ± 1.1a, b

0.007

0.022

 cg27292431

6

160543261

1stExon

43.2 ± 0.6

46.9 ± 2.9

42.1 ± 1.2

48.4 ± 1.5a, b

0.008

0.022

 Average DNA methylation (13 CpG sites)

56.5 ± 0.2

58.8 ± 1.1a, b

55.7 ± 0.4

58.8 ± 0.6a, b

0.0002

 

 DNA methylation promoter region : TSS1500 and TSS200 (4 CpG sites)

42.7 ± 0.5

45.8 ± 2.3b

40.6 ± 0.8a

47.6 ± 1.2a, b

0.0001

 

SLC22A3

 cg22117918

6

160769114

TSS1500

8.3 ± 0.2

9.1 ± 0.9

7.9 ± 0.3

9.7 ± 0.5a, b

0.033

0.138

 cg25313204

6

160768801

TSS1500

42.9 ± 0.6

48.2 ± 2.8

42.9 ± 1.0

47.8 ± 1.5a, b

0.014

0.107

 cg06295784

6

160771074

Body

40.7 ± 0.5

44.3 ± 2.5

39.6 ± 10.9

44.8 ± 1.3a, b

0.012

0.107

 cg13280882

6

160771574

Body

77.3 ± 1.4

91.9 ± 6.4a, b

77.3 ± 2.4

85.9 ± 3.4a, b

0.033

0.138

 cg11696576

6

160815734

Body

45.1 ± 0.6

52.0 ± 2.7a, b

42.3 ± 1.0a

49.2 ± 1.4a, b

0.0002

0.005

 cg04794858

6

16086035

Body

91.3 ± 0.3

89.6 ± 1.3

90.9 ± 0.5

89.0 ± 0.7a, b

0.036

0.138

 Average DNA methylation (23 CpG sites)

56.0 ± 0.2

57.9 ± 0.8a, b

55.7 ± 0.3

56.9 ± 0.4b

0.033

 

 DNA methylation promoter region: TSS1500 and TSS200 (5 CpG sites)

31.2 ± 0.2

32.8 ± 0.9b

30.8 ± 0.3

32.6 ± 0.5a, b

0.013

 

SLC47A1

 cg01530032

17

19435805

TSS1500

31.7 ± 0.7

38.5 ± 3.0a, b

30.6 ± 1.1

39.7 ± 1.6a, b

0.0001

0.001

 cg25387636

17

19436896

TSS1500

7.4 ± 0.2

8.0 ± 1.1

6.3 ± 0.4a

8.5 ± 0.6b

0.019

0.057

 cg15971010

17

19436900

TSS1500

10.1 ± 0.3

11.2 ± 1.5

8.6 ± 0.5a

12.0 ± 0.8a, b

0.007

0.028

 cg15014549

17

19437003

TSS200

3.7 ± 0.7

3.7 ± 0.3

3.8 ± 0.1

4.4 ± 0.2a, b

0.007

0.028

 cg07829432

17

19437013

TSS200

3.8 ± 0.1

4.7 ± 0.4

3.8 ± 0.2

5.2 ± 0.2a, b

<0.0001

< 0.0001

 cg20930201

17

19437691

Body

7.7 ± 0.2

9.2 ± 0.9b

6.7 ± 0.3a

9.1 ± 0.5a, b

0.0009

0.007

 cg26959235

17

19437889

Body

12.7 ± 0.2

11.9 ± 1.1

12.7 ± 0.4

10.8 ± 0.6a, b

0.033

0.086

 cg24151087

17

19450271

Body

9.9 ± 0.2

10.5 ± 1.2

9.8 ± 0.4

12.1 ± 0.6a, b

0.018

0.057

 cg16887170

17

19451180

Body

84.0 ± 0.4

83.3 ± 1.8

81.7 ± 0.7a

83.0 ± 0.9

0.036

0.086

 cg12550399

17

19482275

3′ UTR

64.2 ± 0.8

67.0 ± 3.6

62.8 ± 1.3

71.9 ± 1.9a, b

0.002

0.011

 Average DNA methylation (24 CpG sites)

33.1 ± 0.1

34.0 ± 0.6b

32.7 ± 0.2

34.5 ± 0.3a, b

0.0001

 

 DNA methylation promoter region: TSS1500 and TSS200 (11 CpG sites)

12.2 ± 0.2

13.2 ± 0.8

11.6 ± 0.3

14.3 ± 0.4a, b

<0.0001

 
  1. Data are shown as mean ± SEM. All data is adjusted for age, sex, and NASH. Post-hoc analysis is used for comparisons between groups after ANCOVA. q values are based on false discovery rate (FDR) tests after ANCOVA
  2. a P < 0.05 compared to non-diabetic subjects
  3. b P < 0.05 compared to metformin treatment